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Clearance of apoptotic cells (efferocytosis) is
achieved through phagocytosis by professional or
amateur phagocytes. It is critical for tissue homeo-
stasis and remodeling in all animals. Failure in this
process can contribute to the development of inflam-
matory autoimmune or neurodegenerative diseases.
We found previously that the PALL-SCF E3-ubiquitin
ligase complex promotes apoptotic cell clearance,
but it remained unclear how it did so. Here we
show that the F-box protein PALL interacts with
phosphorylated ribosomal protein S6 (RpS6) to pro-
mote its ubiquitylation and proteasomal degrada-
tion. This leads to RAC2 GTPase upregulation and
activation and F-actin remodeling that promotes
efferocytosis. We further show that the specific role
of PALL in efferocytosis is driven by its apoptotic
cell-induced nuclear export. Finding a role for RpS6
in the negative regulation of efferocytosis provides
the opportunity to develop new strategies to regulate
this process.
INTRODUCTION
Innate immunity is the first line of host defense of all animals. It
limits infection by clearing pathogens (Modlin, 2012). Humoral
responses in innate immunity have been studied extensively
(Shishido et al., 2012), but its cellular responses are still poorly
understood. This includes phagocytosis, the process by which
specialized cells, the phagocytes, recognize, engulf, and digest
pathogens, tissue debris, and necrotic cells during infection and
in wound healing (Brown, 1995). Phagocytosis is also critical
for tissue homeostasis because approximately 50–70 billion of
our cells die daily by apoptosis (Han and Ravichandran, 2011).
Professional and amateur phagocytes rapidly clear theseDeveapoptotic cells (ACs), a process known as efferocytosis (Henson
et al., 2001). Failure to clear ACs can promote neurodegenera-
tion and autoimmunity (Fuller and Van Eldik, 2008; Mun˜oz
et al., 2010). It has also been associated with age-related macu-
lar retinal degeneration and with systemic lupus erythematosus
(Finnemann et al., 2002; Hanayama et al., 2006). A thorough
understanding of phagocytosis is essential to design new drugs
to fight infection and to prevent and/or treat neurodegenerative
and autoimmune diseases.
Drosophila is an ideal model organism in which to study innate
immune responses, including phagocytosis (Ferrandon et al.,
2007). It has macrophage-like cells (Tepass et al., 1994), and
Drosophila Schneider S2 cells behave like macrophages and
are amenable to RNAi and biochemistry (Schneider, 1972). Using
genetic and genome-wide RNAi screens, we previously identi-
fied several molecules required for efferocytosis, including
Pallbearer (PALL), an F-box protein that acts within a SkpA/
dCullin-1/F-box (SCF) complex (Silva et al., 2007). This PALL-
SCF complex functions as an E3-ubiquitin ligase to promote
efficient AC clearance (Silva et al., 2007).
E3-ubiquitin ligases are involved in a variety of biological
processes where the F-box protein is generally responsible for
the binding specificity of the substrate to be degraded via the
proteasome (Deshaies, 1999). Many F-box proteins have spe-
cific protein-protein interaction domains, such as leucine-rich
repeats, WD-40 repeats, Sec7, or others, that have facilitated
the identification of their substrate(s). However, many other
F-box proteins do not have such domains, making it more diffi-
cult to identify their substrates. PALL belongs to this subclass,
and what its substrate(s) for degradation may be in efferocytosis
is not yet known.
Here we used both biochemistry and genetics to find the PALL
substrate(s). We show that PALL interacts with the ribosomal
protein S6 (RpS6) and that this interaction depends on the phos-
phorylation of RpS6. Treatment of S2 cells with the proteasome
inhibitor MG132 results in accumulation of polyubiquitylated
RpS6, revealing a role for the ubiquitin-proteasome path-
way in the regulation of RpS6 levels. The polyubiquitylation
and degradation of RpS6 are PALL-dependent because welopmental Cell 32, 19–30, January 12, 2015 ª2015 Elsevier Inc. 19
observed less polyubiquitylated forms of RpS6 in pall RNAi-
treated S2 cells. RNAi of RpS6 enhances AC engulfment in S2
cells, and, conversely, overexpressing RpS6 in embryonic
macrophages partially inhibits AC clearance in vivo. Mutation
of RpS6 suppresses the AC clearance defect phenotype of a
pall mutant allele. We found that pall and RpS6 mutant macro-
phages have opposite F-actin phenotypes, with F-actin accumu-
lation in pall mutants and diminished F-actin in RpS6 mutants.
Also, pall andRpS6RNAi-treated S2 cells have opposite staining
phenotypes for RAC. RAC regulates actin cytoskeleton during
AC clearance in Caenorhabditis elegans and mammalian sys-
tems (Gumienny et al., 2001; Kinchen et al., 2005), and RAC2
is required for efferocytosis in Drosophila S2 cells (Cuttell et al.,
2008). Cells treated with pall RNAi have less total and active
RAC2, whereas RpS6 RNAi-treated S2 cells have more. Impor-
tantly, overexpressing RAC2 in pall mutant macrophages
rescued their phagocytosis defect. Therefore, we propose that
the PALL/SCF complex promotes the proteasomal degradation
of RpS6, which acts as a negative regulator of efferocytosis. This
degradation leads to F-actin cytoskeleton remodeling via the
upregulation and activation of RAC2, thereby promoting phago-
cytosis. Finally, we show that PALL is not required for phagocy-
tosis of bacteria and that its specificity in efferocytosis is driven
by its AC-induced nuclear export.
RESULTS
PALL Physically Interacts with RpS6
We proposed previously that PALL promotes efferocytosis by
promoting ubiquitylation and proteasomal degradation of one
ormore phosphorylated substrates (Silva et al., 2007). To identify
the PALL substrate(s), we established three stable S2 cell lines
that express hemagglutinin (HA)-tagged, full-length PALL (HA-
PALLFL), its F-box-deleted version (HA-PALLDF), or the F-box
protein SLIMB (HA-SLIMB), which plays a role in innate immunity
but not in efferocytosis (Khush et al., 2002; Silva et al., 2007). We
used protein extracts of these stable cell lines in immunoprecip-
itations (IPs) with HA antibody (Ab) and carried out comparative
analyses of the IPs on SDS-PAGE. We found one endogenous
protein of around 26 kDa in coimmunoprecipitations with both
HA-PALLFL and HA-PALLDF but not with HA-SLIMB. Using
MALDI-TOF mass spectrometry (MS), we identified this interac-
tor as the ribosomal protein S6 (RpS6), a component of the 40S
subunit of the ribosome (Figure 1A). Although ribosomal proteins
are abundant and often pulled nonspecifically in IPs, RpS6 was
the only ribosomal protein being consistently pulled down with
HA-PALLFL and HA-PALLDF, but not with HA-SLIMB, in three
other independent IPs subjected to comparative tandem MS
(Figure 1B). RpS6 sequences recovered in the MS are indicated
in blue in Figure 1C. Treatment of S2 cells with cycloheximide, an
inhibitor of protein translation, did not significantly enhance or
reduce the ability of S2 cells to clear ACs, arguing that the role
of RpS6 in efferocytosis is independent of its role as a compo-
nent of the small ribosomal subunit in the context of protein syn-
thesis (Figure S1A available online). Deleting the F-box domain
of PALL prevents its interaction with SkpA (Silva et al., 2007;
Figure 1D), eliminating the possibility that RpS6 is binding to
the other components of the PALL-SCF complex. We further
confirmed the interaction between PALL and RpS6 in cotrans-20 Developmental Cell 32, 19–30, January 12, 2015 ª2015 Elsevier Infections in S2 cells using HA-PALLFL- and RpS6-FLAG-tagged
constructs (Figure 1D) as well as HA-PALLFL-, HA-PALLDF-,
and RpS6-V5-tagged constructs (Figure 1E; Figure S1B). There-
fore, RpS6 interacts with PALL and is a candidate substrate
of PALL.
RpS6 Phosphorylation Is Required for Its Interaction
with PALL
RpS6 is a component of the 40S subunit of the ribosome and
the substrate of several mammalian serine/threonine protein
kinases that can phosphorylate RpS6 at S233, S235, S239,
S242, and S245 (S indicated in red in Figure 1C), all of which
are highly conserved (Radimerski et al., 2000). One of the
RpS6 peptide identified by MS included a carboxy-terminal
peptide that contains the conserved serines, as highlighted in
blue in Figure 1C. Substrates of F-box proteins are generally
phosphorylated prior to specifically interacting with their
respective F-box proteins. To address whether RpS6 phosphor-
ylation at its conserved serines is a prerequisite for its interac-
tion with PALL, we generated a V5-tagged mutated construct
of RpS6 under the control of the metallothionin (MT)-inducible
promoter where all five serines were mutated into alanines
(MT-RpS6(S/A)-V5). We cotransfected this construct into S2
cells with either HA-PALLFL and HA-PALLDF constructs, car-
ried out IPs with HA Ab, and probed for RpS6(S/A)-V5 using
V5 Ab on western blots (WBs). RpS6(S/A)-V5 could no longer
coimmunoprecipitate with either HA-PALLFL or HA-PALLDF
(Figure 1E). Therefore, serine phosphorylation of RpS6 is
required for its interaction with PALL.
PALL Promotes Polyubiquitylation and Proteasomal
Degradation of RpS6
The interaction of phosphorylated RpS6 with PALL suggests
that RpS6 is a target of the PALL-SCF complex for polyubiqui-
tylation and proteasomal degradation. This hypothesis was
further strengthened by our observation that the input level of
expression of the mutated form of RpS6, RpS6(S/A)-V5, in S2
cells was greater than that of RpS6-V5 under similar cotrans-
fection conditions as well as in the sole presence of endoge-
nous PALL (see V5 input in Figure 1E). This result suggests
that mutating the serine phosphorylation sites of RpS6 into
alanines, which abolishes RpS6 interaction with PALL, prevents
its ubiquitylation and degradation via the proteasome. To test
this, we asked whether RpS6 could accumulate when inhibiting
the proteasome. We overexpressed RpS6-V5 in HA-PALLFL-
stable S2 cells in the presence or absence of the proteasome
inhibitor MG132 and quantified the level of RpS6 protein in
WBs. RpS6-V5 accumulated in the presence of MG132 (Fig-
ure 2A) because its expression level increased significantly by
34.2% ± 17.1% (p < 0.05) when compared with that in the
absence of MG132 (Figure 2B). We could not evaluate the
levels of phosphorylated RpS6 because commercial antibodies
against mammalian phosphorylated RpS6 do not cross-react
with Drosophila RpS6.
To further address whether RpS6 is a substrate of PALL-SCF
for ubiquitylation, we overexpressed RpS6-V5 with an Act5C-
ubiquitin (Act5C-Ub) construct in HA-PALLFL-stable S2 cells in
the presence or absence of the proteasome inhibitor MG132.
We immunoprecipitated RpS6-V5 with V5 Ab and performed ac.
Figure 1. PALL Physically Interacts with Phosphorylated RpS6
(A) SDS-PAGE and Coomassie blue staining of HA Ab immunoprecipitates of HA-PALLFL-, HA-PALLDF-, or HA-SLIMB-expressing S2 cell extracts. RpS6 is
identified by differential band cutout, and MALDI-TOF is indicated by an arrow. Lane 1, protein ladder; lane 2, HA-SLIMB (unrelated F box); lane 3, HA-PALLFL;
lane 4, HA-PALLDF (F box-deleted PALL); lane 5, control S2 cells.
(B) Flow chart of IPs and tandem MS with HA-SLIMB (control irrelevant F-box protein), HA-PALLFL, and HA-PALLDF (F-box-deleted PALL) stable S2 cells.
(C) Primary amino acid sequence of endogenous RpS6. In blue are sequences found by tandem MS. Phosphorylated serines are indicated in red.
(D) IPs with HA Ab of crude protein extracts from transiently transfected S2 cells expressing RpS6-FLAG or SkpA-FLAG and HA-SLIMB, HA-PALLFL, or HA-
PALLDF. Shown are RpS6-FLAG immunoprecipitates with HA-PALLFL and HA-PALLDF but not with HA-SLIMB. As a control, SkpA-FLAG immunoprecipitates
with HA-PALLFL but not HA-PALLDF. Inputs are given by WB detection on protein extracts of RpS6-FLAG and SkpA-FLAG or of HA-SLIMB-, HA-PALLFL-,
and HA-PALLDF-expressing cells with FLAG and HA Abs, respectively (see also Figure S1B).
(E) IPs with HA Ab of protein extracts from S2 cells expressing RpS6-V5 or its RpS6(S/A)-V5 mutant with HA-PALLFL or HA-PALLDF, followed by V5 Ab WB.
The PALL/RpS6 interaction is lost when RpS6 is mutated at its serine phosphorylation sites.
See also Figure S1.WB with ubiquitin (Ub) Ab to assess whether RpS6 could be
ubiquitylated (Figure 2C). We detected several polyubiquitylated
forms of RpS6 in the presence of MG132 but not in its absence
(Figure 2C). These results demonstrate conclusively that RpS6
is a substrate for polyubiquitylation.
We then asked whether ubiquitylation of RpS6 was PALL-
dependent. For this, we repeated the above experiments in
pall RNAi-treated S2 cells in the presence of MG132. We found
that the level of detectable polyubiquitylated RpS6 was reduced
by almost 55% when compared with MG132-treated control S2
cells (Figures 2D and 2E). As in Figure 2A, the level of RpS6-V5
expression was higher in MG132-treated cells than in untreated
control S2 cells (see V5 input WB in Figure 2D). Together, these
results demonstrate a previously unappreciated role for the
ubiquitin-proteasome pathway in the regulation of RpS6 protein
levels. Therefore, PALL is required for the specific interaction
of RpS6 with the PALL-SCF complex and subsequent RpS6
polyubiquitylation and proteasomal degradation.DeveAn RpS6 Loss-of-Function Mutation Suppresses
the Loss-of-Function Phenotype of pall
To further assess whether RpS6 acts as a substrate for polyubi-
quitylation and proteasomal degradation via the PALL-SCF
complex in vivo, we asked whether RpS6 and pallmight interact
genetically. Because a loss of function of pall is expected to
result in RpS6 accumulation, we askedwhether a loss of function
of RpS6 might suppress the loss-of-function phenotype of pall,
i.e., restore AC clearance in the pall-null allele. Previously
characterized pall alleles were not single mutants of pall but
also affected neighboring genes (Silva et al., 2007). Therefore,
we generated a pallko-null allele by homologous recombination
(Figures S2A–S2B’’). As anticipated, pallko macrophages have
a defect in phagocytosis of ACs in vivo when compared with
wild-type macrophages (Figure S2C). Of note is that pallko
does not appear to have any obvious growth-related phenotypes
at any developmental stages. Although we did not look exten-
sively for these types of phenotypes at the cellular level, thelopmental Cell 32, 19–30, January 12, 2015 ª2015 Elsevier Inc. 21
Figure 2. RpS6 Is a Substrate of PALL for Polyubiquitylation and Proteasomal Degradation
(A) HA-PALLFL stable S2 cells transfected with RpS6-V5 and treated with or without MG132, followed by WB with V5 Ab. The tubulin WB served as a loading
control.
(B) Graph summarizing the quantification of (A). Bars represent the relative percentage when compared with untreated (MG132) cells ± SEM of three inde-
pendent experiments.
(C) HA-PALLFL stable S2 cells transfected with RpS6-V5 and Act5C-Ub constructs and treated with or without MG132. V5 Ab immunoprecipitates of RpS6 were
blotted with Ub Ab to detect polyubiquitylated forms of RpS6. The input of RpS6-V5 protein is shown by WB of crude cell extracts with V5 Ab.
(D) The same experiments as in (C) but with or without pretreating the S2 cells with pall RNAi prior to MG132 treatment and IP with V5 Ab andWBwith Ub Ab. The
input of RpS6-V5 protein is shown by WB of crude cell extracts with V5 Ab.
(E) Graph showing the relative quantification of the mean percent ± SEM of ubiquitylated RpS6 in S2 cells without MG132 (w/o MG132) and pall-RNAi cells in the
presence of MG132 (w/MG132 pall RNAi) compared with control S2 cells with MG132 (w/MG132).phosphorylation of RpS6 in the context of efferocytosis is also
independent of the target of rapamycin (TOR) and S6 kinase
pathway (H.X. and N.C.F., unpublished data).
We then crossed our pallko to a previously characterized
strong hypomorphic loss-of-function allele of RpS6,RpS6WG1288
(Watson et al., 1992), and assessed the phagocytosis pheno-
types and phagocytic indices (PIs) of homozygous pallko macro-
phages that were either heterozygous or homozygous for
RpS6WG1288 by CRQ Ab and 7-amino actinomycin-D (7-AAD)
double staining and confocal microscopy (Silva et al., 2007; Fig-
ure 3). Double-homozygous mutant macrophages were capable
of engulfing ACs (Figure 3C) with a PI of 2.61 ± 0.28, similar
to that of control macrophages (Figure 3D) and of RpS6WG1288
homozygous macrophages (Figure 3A) with PIs of 2.47 ± 0.16
and 2.4 ± 0.22, respectively (Figure 3D) (p > 0.05). Therefore,
loss of function of RpS6 rescued the phagocytosis phenotype
defect of homozygous pallko mutant macrophages, which
had a PI of 1.35 ± 0.12, whereas mutating one copy of RpS6
did not significantly affect the homozygous pallkomutant pheno-22 Developmental Cell 32, 19–30, January 12, 2015 ª2015 Elsevier Intype (Figures 3B and 3D) (p < 0.05 compared with control, and
p > 0.05 when compared with pallko). Together, these results
demonstrate that RpS6 and pall interact genetically and act in
the same pathway in vivo, where RpS6 acts downstream of
pall as its substrate for polyubiquitylation and proteasomal
degradation.
RpS6 Acts as a Negative Regulator of Efferocytosis
RpS6 is a substrate of PALL for proteasomal degradation to
promote AC clearance, therefore arguing that RpS6 acts in mac-
rophages as a negative regulator of this process. In a genome-
wide RNAi screen for genes required in AC clearance in S2 cells,
we found that RpS6 RNAi treatment of S2 cells with both
DRSC18712 and DRSC25010 could enhance phagocytosis of
ACs (http://www.flyrnai.org; Figure 4). Compared with mock-
treated S2 cells (Figure 4A), RpS6 RNAi-treated S2 cells with
DRSC25010 weremore than 2-fold more phagocytic when given
a same amount of ACs (Figures 4C and 4G). RNAi-treatments of
two other components of the small ribosome subunit, such asc.
Figure 3. A Loss-of-Function Mutation of
RpS6 Suppresses the Loss-of-FunctionMu-
tation Phenotype of pall In Vivo
(A–C) Confocal micrographs of RpS6WG1288 ho-
mozygous embryos, RpS6WG1288/+; pallko260/
pallko260 embryos, and RpS6WG1288; pallko260
double-homozygous embryos stained with the
CRQ Ab (green) and 7-AAD (red). Dotted white
circles outline single macrophages. Scale bars,
10 mm.
(D) Graph showing the mean PIs ± SEM for each
genotype. *, homozygous alleles.
See also Figure S2.RpS10b (the knockdown of which enhances phagocytosis of
Listeria monocytogenes [Agaisse et al., 2005]) and RpS2, served
as controls and did not significantly affect the ability of S2 cells
to engulf ACs (Figures S3A and S3B).
We further tested whether RpS6 could act as an inhibitor of
efferocytosis in vivo by driving the expression of two inde-
pendent UAS-RpS6 transgenic lines under the control of the
macrophage-specific crq-Gal4 transgene (Figures 4D–4F and
4H). Overexpressing RpS6 with either UAS-RpS6 lines resulted
in a >30% decrease in phagocytosis by embryonic macro-
phages in vivo (compare Figures 4E and 4F with Figure 4D),
with PIs of 2.36 ± 0.27 and 2.32 ± 0.31 versus 3.44 ± 0.47 in
the crq-gal4 control (p < 0.05) (Figure 4H). The macrophage-
specific overexpression of other components of the small ribo-
some subunits, including RpS2 and RpS10b, did not affect
their phagocytic ability (Figure S3C). Therefore, RpS6 acts as a
negative regulator of efferocytosis, which further fits with its
role as a PALL substrate for polyubiquitylation and proteasomal
degradation, thereby promoting efficient engulfment of ACs.
Furthermore, this role for RpS6 appears to be independent of
its ribosomal function.
PALL and RpS6 Regulate F-Actin Cytoskeleton
Rearrangement in Efferocytosis
How do PALL and RpS6 act in regulating AC clearance? F-actin
cytoskeleton rearrangement is an important hallmark of phago-
cytosis (Allen and Aderem, 1996). Recently, phosphorylated
RpS6 was attributed a role in regulating F-actin organization
and junctional protein recruitment at the blood-testis barrier dur-
ing spermatogenesis, where increased level of phosphorylated
RpS6 disrupted the barrier and colocalized with disorganized
F-actin (Mok et al., 2012). Therefore, we next asked whether
pall facilitates AC clearance by promoting RpS6 polyubiquityla-Developmental Cell 32, 19–3tion and degradation and subsequent
F-actin remodeling. We first assessed
the F-actin phenotype of mock- and pall
RNAi-treated S2 cells (Figures S4A and
S4B, respectively) by phalloidin staining.
The F-actin immunostaining increased
by 73% ± 6.4% in pall RNAi-treated S2
cells compared with the mock-treated
cells (Figure S4C). The pallmRNA expres-
sion was down by about 75% in pall
RNAi-treated S2 cells compared withmock-treated cells (Figure S4D). To find out whether pall regu-
lates F-actin in vivo, we further assessed the actin phenotype
of pallko macrophages. As for Phalloidin staining in pall RNAi-
treated S2 cells, F-actin immunostaining increased in pallko
macrophages (Figure 5B) compared with that of wild-type
macrophages (Figure 5A). In contrast, F-actin immunostaining
was weaker in RpS6WG1288 mutant macrophages (Figure 5C)
compared with wild-type macrophages (Figure 5A), therefore
having the anticipated opposite phenotype. Similar results
were obtained with phalloidin staining of pall and RpS6 mutant
macrophages in vivo (data not shown). These data argue that
PALL and RpS6 play a role in regulating the F-actin cytoskeleton
in Drosophila macrophages in vivo. Furthermore, pall RNAi-
treated S2 cells were more rounded than mock-treated cells,
with F-actin distributed evenly around their cell cortex, whereas
F-actin staining was weaker in RpS6-RNAi cells and more local-
ized at their basal membrane (i.e., at their point of contact with
the glass slide) (Figures 5D and 5E). RpS6 RNAi-treated cells
spread onto glass slides and made more membrane ruffles
than mock-treated cells (Figures 5D and 5E). Tubulin and actin
monomers expression levels in pall or RpS6 RNAi cells
were comparable with that of mock-treated cells (Figure 6A).
Therefore, PALL and RpS6 regulate F-actin cytoskeleton rear-
rangement in vivo and in S2 cells.
PALL and RpS6 Regulate the Drosophila RAC2 Level
and Activity in Efferocytosis
The small GTPase RAC has been shown to play an important
role in AC clearance in both C. elegans and mammalian systems
(Gumienny et al., 2001; Kinchen et al., 2005) by promoting actin
remodeling. In a genome-wide RNAi screen for genes required
for AC clearance by S2 cells, we found a role for the small
GTPase RAC2 but not for the other RAC family members,0, January 12, 2015 ª2015 Elsevier Inc. 23
Figure 4. RpS6 Acts as a Negative Regulator of AC Clearance
(A–C) Phagocytosis of ACs bymock-treated (A),Rab5RNAi-treated (B), or RpS6RNAi-treated (C) S2 cells. Live cells are blue, and engulfed FITC-labeled ACs are
green. Scale bars, 200 mm.
(D–F) Merged confocal images of yw; +; crq-Gal4, UAS-eGFP (wild-type reference) (D) and yw; UAST-RpS6; crq-Gal4, UAS-eGFP macrophages with two in-
dependent transgenic UAST-RpS6 lines, [1] and [2], in (E) and (F), respectively. ACs are stained with 7-AAD (red), and GFP-expressing macrophages appear
green. Scale bars, 10 mm.
(G) Graph summarizing the quantification of (A–C) with rab5-RNAi S2 cells as a control. Bars represent the relative phagocytosis compared with mock-treated S2
cells ± SEM of three independent experiments with duplicated wells.
(H) Graph showing the mean PIs ± SEM for each genotype in (D–F).
See also Figure S3.RAC1 and MTL (Mig-2 like) (Cuttell et al., 2008). We asked
whether PALL and RpS6 might regulate RAC levels and/or activ-
ity in S2 cells. On a WB of total protein extracts from RNAi-
treated S2 cells, we observed that there was approximately
57% less and 40% more total RAC in pall RNAi and RpS6
RNAi cells, respectively, than in mock-treated cells (Figures 6A
and 6B). We then assessed the localization of RAC and
active RAC by immunostaining in these cells. Mammalian24 Developmental Cell 32, 19–30, January 12, 2015 ª2015 Elsevier InRAC1 Ab staining, which cross-reacts with Drosophila RAC1
and 2 (catalog no. 23A8, Thermo Scientific), confirmed our
WB findings because RpS6- and pall RNAi-treated S2 cells ex-
hibited increased and decreased immunostainings, respectively,
compared with mock-treated S2 cells (Figure S5A). To find
out whether RAC levels resulted in similar active RAC levels
in the cells, we also stained these RNAi-treated cells with a
monoclonal Ab directed against active mammalian RAC1. Thisc.
Figure 5. PALL Promotes Actin Remodeling
during AC Clearance
(A–C) Confocal micrographs of Actin (green)
and CRQ (red) immunostaining of yw embryos
(wild-type [WT] control in [A]), pallko260 (B), and
RpS6WG1288 (C) mutant embryos.
(D) Confocal micrographs of mock-treated,
pall RNAi, or RpS6 RNAi S2 cells stained with
phalloidin. z stack images through the cells were
collected 1.74 mm apart (the basal membrane is
in contact with the glass slide). Scale bars, 10 mm.
(E) Schematic summarizing F-actin staining
(green) distribution and cell shape for mock-
treated and pall and RpS6 RNAi S2 cells seen
in (D). Green lines and blue circles represent
actin and nuclei, respectively. Black lines repre-
sent the slides.
See also Figure S4.Ab cross-reacted withDrosophilaRAC2 specifically (Figure S5B)
and labeled the membranes of all treated cells. Again, pall- and
RpS6 RNAi-treated S2 cells showed reduced and increased
staining, respectively, compared with mock-treated S2 cells
(Figure 6C). We then asked whether we could rescue the phago-
cytosis defect of pall by overexpressing the Drosophila UAS-
Rac2 transgene in the pallko mutant under the control of the
macrophage-specific crq-gal4 driver. As previously for pallko,
crq-gal4;pallko homozygous macrophages had a significantly
diminished PI of 1.44 ± 0.12 compared with UAS-Rac2/+;
crq-gal4/+;pallko/+ heterozygous control macrophages (PI =
2.41 ± 0.13, p < 0.001), whereas pallko rescue macrophages
that overexpressed UAS-Rac2 under the control of crq-gal4
(UAS-Rac2/+;crq-gal4/+;pallko) had a PI of 2.09 ± 0.19, which
was statistically significantly rescued compared with that of
crq-gal4;pallko homozygous macrophages (p = 0.01) but not
statistically different from the UAS-Rac2/+;crq-gal4/+;pallko/+
heterozygous control (p = 0.3) (Figure 6D; Figures S5C–S5E).
Therefore, PALL allows for the degradation of RpS6 via the pro-
teasome that leads to the upregulation and activation of RAC2
and F-actin rearrangement to promote efferocytosis in vivo.
Nuclear Translocation of PALL in Response to ACs
Confers Its Phagocytic Specificity
Considering the role of PALL upstream of RAC2 activation in
efferocytosis, and because bacteria are cleared by Drosophila
hemocytes via RAC2-mediated phagocytosis (Avet-Rochex
et al., 2007), we next asked whether pallko mutants were
susceptible to infection. Survival rates of Gram-negativeDevelopmental Cell 32, 19–3Pectobacterium carotovorum (also known
as Erwinia carotovora 15 [Ecc15]) and
Gram-positive Enterococcus faecalis (Ef)
(Figure S6A), as well as their bacterial
loads (Figure S6B), were similar in pallko
mutant flies and control flies. Injections
of Alexa 488 (green) Escherichia coli
in pallko (Figure S6C’) and their control
flies (Figure S6C) or of Alexa 488 Staphy-
lococcus aureus (data not shown) or
their pH-sensitive pHrodo-red equivalent(data not shown; Figures S6D and S6D’) did not reveal any defect
in their uptake (Figures S6C and S6C’) or in their phagosomal
degradation (Figures S6D and S6D’). The pallko flies survived
E. coli (Figure S6E) and S. aureus (Figure S6F) septic injuries
equally well as their controls, and the loss of pall did not exacer-
bate the phenotype of mutant flies of the IMD pathway that are
susceptible to a low dose of infection by E. coli (Figure S6E).
Therefore, pall is not required for bacteria killing or phagocytosis
and plays a specific role in efferocytosis.
Having found previously that ACs regulate the expression level
of CRQ, which localizes at the phagosomal membranes during
AC clearance and participates in efferocytosis (Franc et al.,
1996, 1999), we askedwhether ACs could regulate PALL expres-
sion and/or its localization. PALL has two potential nuclear
export signals (NESs) at its amino acids L6 and L10, as predicted
by the NetNES 1.1 server (la Cour et al., 2004; Figure S6G). We
independently expressed in S2 cells a wild-type HA-tagged
PALL (HA-PALLFL; Figure S6H; Movie S1) and versions of
PALL in which the leucines of its NES were mutated into alanines
(HA-NESPALL; Figure S6H; Movie S2) or in which the NES was
replaced by a nuclear localization signal (NLS) (HA-NLSPALL;
Figure S6H; Movie S3). After staining these cells with a HA Ab
and either DAPI or DRAQ5 DNA dyes, we found that both HA-
NESPALL (Figure 7B) and HA-NLSPALL (Figure 7C) were strictly
localized to the nuclei of all transfected S2 cells as anticipated.
However, although HA-PALLFL was expressed in the nuclei of
most transfected S2 cells, it was also found to localize both in
the nuclei and cytoplasm of all transfected S2 cells that were
bound to/engulfing and/or had fully ingested ACs (Figure 7A;0, January 12, 2015 ª2015 Elsevier Inc. 25
Figure 6. RpS6 Targeting by PALL Pro-
motes RAC Upregulation and Activation
(A) WB of protein extracts from mock-treated,
pall RNAi, or RpS6 RNAi S2 cells probed with
tubulin and monomeric actin (internal controls)
and mammalian RAC1 Abs.
(B) Graph showing the percent ± SEM of RAC
protein expression in pall and RpS6 RNAi S2 cells
relative to mock-treated cells (control normalized
at 100%) based on three separate experiments.
(C) Confocal micrographs of mock-treated, pall
RNAi, and RpS6 RNAi S2 cells stained with active
RAC Ab. z stack images through the cells were
collected at 1.74 mm intervals. Scale bars, 10 mm.
(D) Graph showing themean PIs ± SEMof crq-gal4
control, crq-gal4;pallko mutant, and pallko mac-
rophages that overexpress UAS-Rac2 under the
control of crq-gal4. ns, not significant.
See also Figure S5.Movie S1). In contrast, mutated HA-NESPALL never translo-
cated, even when these cells engulfed endogenous ACs (white
arrow, Figure 7B; Movie S2; of note is that endogenous PALL
is present in these cells), and neither did mutated HA-NLSPALL
(Figure 7C; Movie S3). Moreover, HA-PALLFL remained nuclear
in S2 cells that had bound or fully ingested Gram-negative
(E. coli) or Gram-positive (S. aureus) bacteria (Figure 7F). There-
fore, the NES is required for the translocation of PALL from the
nuclei to the cytoplasm of S2 cells in response to ACs, and this
translocation is dependent on the binding/recognition of ACs
(Figures 7D and 7E). These results demonstrate that ACs
play an active role in regulating PALL localization that promotes
efferocytosis and confers PALL its specificity in this process.
DISCUSSION
The PALL-SCF complex and proteasomal degradation are
required for efficient AC engulfment (Silva et al., 2007). However,
it was not clear how this promoted efferocytosis. Here we
provide insights into the molecular mechanisms by which PALL
promotes efferocytosis. Upon recognition and binding of ACs,
PALL translocates from the nucleus to the cytoplasm, where it
forms a PALL-SCF complex and specifically interacts with and
targets phosphorylated RpS6 to polyubiquitylation and degra-
dation via the 26S proteasome, which results in an increased
level and activity of RAC2, followed by actin remodeling to
promote efferocytosis.
RpS6, a component of the small 40S subunit of the ribosome,
has highly conserved serines that are phosphorylated by S6 and
RSK kinases following a wide variety of stimuli (Meyuhas, 2008).
RpS6 has long been thought to be required for various functions,
including global protein synthesis, the translation of mRNAs
containing a 50 terminal oligopyrimidine tract (TOP mRNAs),
cell size and proliferation, and glucose homeostasis (Meyuhas,
2008). However, RpS6P/ knockin mice in which all five serines
of RpS6 were mutated into alanines show a 2.5-fold increase26 Developmental Cell 32, 19–30, January 12, 2015 ª2015 Elsevier Inc.rather than a decrease in global protein
synthesis and have a similar rate of
translational activation of TOP mRNAs(Ruvinsky et al., 2005). RpS6P/ mice have similar weights as
wild-type mice, although some of their cells are small because
of impaired growth as they undergo compensatory proliferation
(Ruvinsky et al., 2005). RpS6P/ mice also have reduced
glucose disposal capacity because of a 2-fold reduction in the
secretion of circulating and pancreatic insulin by small b cells
(Ruvinsky et al., 2005). In at least one study, intravenous injection
of mice with rat breast carcinoma cells resulted in poorly phago-
cytic alveolar macrophages with reduced cell-autonomous
glucose oxidation that led to tumor metastasis (Gudewicz and
Saba, 1977). It will be interesting to find out whether reduced
glucose oxidation in these alveolar macrophages correlates
with reduced glucose homeostasis because of defective RpS6
regulation.
Drosophila RpS6 appears to play immune-specific roles
because RpS6mutants have overgrown lymph glands (the larval
hematopoietic organs), abnormal proliferation and differentiation
of enlarged hemocytes, and melanotic masses caused by erro-
neous encapsulation of larval tissues (Stewart and Denell,
1993; Watson et al., 1992). These phenotypes suggest that
losing RpS6 results in hemocyte hyperactivation. This is consis-
tent with our data showing that RpS6-RNAi S2 cells are more
phagocytic. We did not, however, observe any increased effero-
cytosis by macrophages in RpS6mutant embryos in vivo. This is
likely due to the limited amount of ACs present in the embryo
compared with the excess of ACs used in our S2 cell assay.
Although RpS6 acts as a negative regulator of efferocytosis,
other proteins of the ribosome small subunit, including RpS2
and RpS10b, do not participate in this process because RNAi
in S2 cells or in vivo overexpression experiments did not reveal
any significant effect on efferocytosis (Figure S3). Yet another
ribosomal protein, RpS17, appears to act as a positive regulator
of efferocytosis because RNAi for RpS17 in S2 cells results
in these cells being less efficient at engulfing ACs (H.X. and
N.C.F., unpublished data). Further experiments will be required
to determine the precise role of RpS17 in AC clearance.
Figure 7. Regulation of PALL Localization
by ACs Confers Its Specificity to Efferocy-
tosis
(A–E) Z stack confocal images through DRAQ5- (A–
C) or DAPI- (D–E) (blue) and HA Ab-double-stained
(red) S2 cells expressing various forms of PALL.
(A) A HA-PALLFL expressing S2 cell that has en-
gulfed an endogenous AC (white arrows) shows
both nuclear (dotted circles surrounding the cell
nuclei of interest) and cytoplasm HA-PALLFL
protein expression, whereas a cell that has not
engulfed nor bound to AC shows HA-PALLFL
strictly in its nucleus.
(B) HA-NESPALL-expressing S2 cells where the
leucine residues of the NES of PALL were mutated
into alanines, which prevents PALL nuclear export
even when cells have engulfed endogenous ACs.
(C) HA-NLSPALL expressing S2 cells where the
NES was replaced by a NLS show its nuclear
localization.
(D and E) A HA-PALLFL expressing S2 cell that has
engulfed an endogenous AC (white arrow) and a
FITC-labeled AC (yellow arrow) (D) and a HA-
PALLFL-expressing S2 cell that is engulfing an
endogenous AC (white arrow) (E) showing both
nuclear (dotted circle around the nucleus) and
cytoplasmic localization of HA-PALLFL.
(F) Nuclear localization of PALL on confocal micrographs of HA Ab-stained (green) HA-PALLFL-expressing S2 cells that have engulfed E. coli and S. aureus
bacteria.
Scale bars, 5 mm. See also Figure S6.However, based on these experiments, we propose that RpS6
acts in efferocytosis independently of its ribosomal function.
Interestingly, mammalian RpS6 can interact with proteins
outside of the ribosome, including heat shock protein 90, alpha-
virus nonstructural protein, and the death-associated protein
kinase (Meyuhas, 2008), and is likely to also have functions
that are independent of the translational machinery.
The nuclear export of PALL in response to ACs, but not to
bacteria, is particularly important because it confers a specific
role for RpS6 in efferocytosis. Indeed, RpS6 RNAi in S2 cells
results in an increase in phagocytosis of the Gram-positive
bacterium L. monocytogenes (Agaisse et al., 2005), although
the specific role of RpS6 in this system is not yet known. We
carried out similar RpS6 RNAi in S2 cells with new validation
amplicons that have no target effects and exposed those S2
cells to fluorescent E. coli and S. aureus bacteria. We also found
that knocking downRpS6 enhanced phagocytosis of both E. coli
and S. aureus (H.X. and N.C.F., unpublished data). Therefore,
RpS6 acts as a negative regulator of bacterial clearance,
although the mechanism by which RpS6 is regulated during
this process is not known. Finally, RpS6 RNAi in S2 cells also
confers tolerance to Drosophila C virus infection, although it
does so by acting in the context of its ribosomal function
together with other ribosomal proteins (Cherry et al., 2005).
Therefore, RpS6 can play many roles in Drosophila immunity,
either directly or indirectly, via its ribosomal function or more
specific functions that merit further investigation.
Phosphorylated RpS6 regulates F-actin organization and
junctional protein recruitment at the blood-testis barrier during
spermatogenesis, where increased levels of phosphorylated
RpS6 disrupt the barrier and colocalize with disorganized F-actinDeve(Mok et al., 2012). F-actin rearrangement in phagocytosis is
regulated by small GTPases of the RAC family. Our results
demonstrate a negative role forDrosophilaRpS6 in AC clearance
and that proteasomal degradation of phosphorylated RpS6 by
PALL-SCF leads to F-actin remodeling via the upregulation
and activation of RAC2. RAC2 is the only GTPase required for ef-
ferocytosis in S2 cells (Cuttell et al., 2008), and overexpressing
RAC2 in pallko mutant macrophages rescued their phagocytosis
defect, therefore linking PALL and RAC2 functions in vivo. Of
further note, myoblasts of RpS6P/ mice have less contractile
proteins, including myosins (Ruvinsky et al., 2009), suggesting
that phosphorylation of RpS6 (and perhaps its degradation) is
required to regulate myosin expression. Together, these obser-
vations further argue in favor of a role for RpS6 in the regulation
of specific proteins in both mouse and Drosophila rather than a
role in global protein synthesis. Whether RpS6 phosphorylation
and proteasomal degradation in Drosophila macrophages or
in other cells result in increased levels of proteins other than
RAC2 to promote efferocytosis or other RpS6-mediated func-
tions will need further investigation.
How the degradation of phosphorylated RpS6 results in higher
levels and activation of RAC2 remains to be determined. Recent
studies, however, have highlighted a role for specific E3 ligases,
including SCFFBXL19 and HACE1, in regulating mammalian RAC1
protein levels in cell migration and tumorigenesis (Torrino et al.,
2011; Zhao et al., 2013). The small GTPase RhoA is also regu-
lated by SCFFBXL19 as well as by another E3 ubiquitin ligase,
Smurf1, in cell migration (Wei et al., 2013). In this instance,
Synaptopodin, an actin-associated protein, can compete with
Smurf1 for binding to RhoA, thereby preventing its degradation
(Asanuma et al., 2006). One possibility is that the accumulationlopmental Cell 32, 19–30, January 12, 2015 ª2015 Elsevier Inc. 27
in the pall mutant of phosphorylated RpS6 may displace such
an inhibitory protein, thereby allowing a specific E3-ubiquitin
ligase to bind to and target RAC2 to polyubiquitylation and
proteasomal degradation. In contrast, in a wild-type context,
the PALL-SCF-mediated ubiquitylation and degradation of
phosphorylated RpS6 may prevent the polyubiquitylation and
degradation of RAC2 by allowing binding of a specific inhibitory
protein to the RAC2-specific E3-ubiquitin ligase, resulting in
elevated levels and activity of RAC2. Of note is that Smurf1
can also regulate a guanine nucleotide exchange factor (GEF)
for yet another small GTPase, CDC42 (Yamaguchi et al., 2008).
Therefore, the regulation of RpS6 may also lead to activation of
RAC2 by indirectly regulating RAC2-specific GEFs or GAPs.
Future studies of the role of Drosophila RpS6 and the regula-
tion of its phosphorylation and levels are likely to provide new
insights into the role and regulation of mammalian RpS6 that
may have implications for the development of treatments to fight
autoimmune and neurodegenerative diseases. Moreover, high
levels of phosphorylated RpS6 correlate with tumor progression
and shorter survival prognostics in patients with esophageal
squamous cell carcinoma (Chaisuparat et al., 2013). Whether
RpS6 plays a role in AC clearance in mammals remains to be
determined, but a lack of engulfment of cancer cells by poorly
phagocytic macrophages with high levels of phosphorylated
RpS6 may favor the development of this cancer. Therefore,
a better understanding of the phosphorylation and regulation
of RpS6 levels and its role in phagocytosis will likely provide us
with drug targets to fight cancer progression.
EXPERIMENTAL PROCEDURES
Fly Strains
Most fly stocks were from the Bloomington Drosophila stock center.
RpS6WG1288 and S6kIIign-D58-1 flies were provided by Leonie M. Quinn
(University of Melbourne) and by F. Rob Jackson (Tufts University School of
Medicine), respectively. UAS transgenic fly lines were generated at BestGene
or supplied by FLYORF. Fly stocks were maintained at 25C in Superfly
incubators (Genesee) on standard medium. For plasmid constructs, see
Supplemental Experimental Procedures.
Generation of HA-PALLFL, HA-PALLDF, and HA-SLIMB Stable
S2 Cell Lines
S2 cells were transfected with Effectene (QIAGEN) according to the sup-
plier’s protocol using 950 ng of HA-PALLFL, HA-PALLDF, or HA-SLIMB
(N terminus-tagged constructs in the pMT-N-3xHA tag vector) DNA and
50 ng of pHygro vector DNA. Cells were resuspended in complete medium
with 300 mg/ml of Hygromycin B to select clones that had integrated pHygro
DNA. Clones were tested for integration of pMT constructs and expression
of HA-tagged proteins by WB following standard protocols after treating
the cells with 0.7 mM of CuSO4 to induce expression under the control of
the MT promoter.
Immunoprecipitations and Tandem MS Analysis
PALL, PALLDF, or SLIMB expression was induced with 0.7 mM CuSO4. Cells
were treated with 25 mM MG132 for 6 hr (Sigma), harvested at 48 and 72 hr
post-CuSO4 treatment, and lysed in 50 mM Tris HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA, and 1% NP40 with Complete EDTA-free protease inhibitor
(Roche). Lysates were centrifuged at 10,0003 g for 30 min, and supernatants
were added to EZ view HA beads (Sigma) overnight at 4C. After several
washes, proteins were eluted in 0.2 M Glycine (pH 2.5) and neutralized with
ammonium bicarbonate. Impurities removed by trichloro-acetic acid precipi-
tation, and samples were subjected to tandem MS analysis (Supplemental
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S2 cells were transfected with Effectene (QIAGEN) according to the supplier’s
protocol. Expression of tagged versions of RpS6, PALL, and SkpA were
induced with CuSO4 at 24 hr, and the cells were harvested and lysed at
48–72 hr after transfection. Lysates were centrifuged at 10,000 3 g for
30 min, and supernatants were incubated with EZ view HA beads or anti-V5
agarose affinity gel (Sigma). Purified samples were resolved by 4%–15%
gradient SDS-PAGE (Bio-Rad). In WBs, Abs were used at the following dilu-
tions: rat anti-HA (Roche) and mouse anti-FLAG (Sigma), 1:2,000; mouse
anti-V5 (Invitrogen), 1:5,000. Anti-rat or anti-mouse horseradish peroxidase
(HRP)-coupled secondary Abs (Jackson ImmunoResearch Laboratories)
were used at a 1:10,000 dilution, followed by ECL detection following the
supplier’s protocol (Pierce).
Stability and Ubiquitylation Assays
For the stability assay, pAc5.1/V5-HisA-RpS6 was transiently transfected into
the HA-PALLFL stable S2 cell line with Effectene (QIAGEN) according to the
supplier’s instructions. The cells were then treated with CuSO4 at 24 hr post-
transfection, followed by MG132 (Sigma) at a concentration of 50 mM for 4 hr.
For the ubiquitylation assay, pAc5.1/V5-HisA-RpS6 and pAc5.1/UB were
transiently transfected into the HA-PALLFL stable S2 cell line with Effectene
(QIAGEN). PALL expressionwas inducedwithCuSO4at 24 hr posttransfection.
The cells were then treatedwithMG132 (Sigma) at a concentration of 50 mM for
4 hr, lysed, and subjected to IPs and WBs as described above. The Ub (P4D1)
mousemonoclonal Ab (SantaCruzBiotechnology)wasused at a 1:200 dilution.
The in vivo phagocytosis assay, phagocytosis index quantification, RNA
interference, and S2 cell phagocytosis assays and their statistical analyses
were performed as in Cuttell et al. (2008) and Silva et al. (2007)).
Statistical Analyses
Statistical p values were derived using ANOVA (for PIs) or Student’s t test
and are indicated in the text and figures.
Ends-Out Gene Targeting
Donor targeting constructs were built by insertion of two 3 kb regions
(upstream and downstream of the pall target gene) into two multiple cloning
sites of the targeting vector pXH87. These constructs were then injected into
w1118 embryos using established methods to obtain transgenics (Bestgene).
The ends-out gene targeting procedure was performed as described in
Chen et al. (2009). To induce double-stranded DNA breaks, heat shock was
performed at 38C for 90 min on day 3 after egg-laying. Target gene-specific
PCR amplification was performed using primers corresponding to a sequence
within the pall gene to verify homozygous knockouts (no PCR product). crq
primer sets were used as a control (Supplemental Experimental Procedures).
Actin staining and RAC immunostaining were performed according to
standard protocols (Supplemental Experimental Procedures).
RAC Quantification
RAC WBs were performed after 3 days of RNAi treatment of S2 cells as
described above. Cells were lysed in in 50 mM Tris HCl (pH 7.4), 0.1% SDS,
200 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 1% NP40, and 10% Glycerol
with Complete EDTA-free protease inhibitor (Roche) and subjected to WBs.
Mouse RAC1 monoclonal Ab (catalog no. 23A8, Thermo Scientific), mouse
Actin Ab (catalog no. A-2066, Sigma), and rabbit a-tubulin Ab (catalog
no. 11H10, Cell Signaling Technology) were used at 1:1,000. Secondary
anti-Mouse HRP-coupled Abs (Jackson ImmunoResearch Laboratories)
were used at 1:10,000, followed by ECL detection.
All experiments with vertebrate animals were performed at the Pocono
Rabbit Farm and Laboratory in accordance with relevant institutional and
national guidelines and regulations. An animal protocol (10-0013-2) was
approved by the Institutional Animal Care and Use Committee of The Scripps
Research Institute.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and three movies and can be found with this article online at
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